Article
Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.
Oncogene - 1 Sept 2026
Lin Chunjie, Liu Jie, Ni Jiacheng, Chen Dingrui, Liu Yafei, Zhu Wanyinhui, Sheng Yinuo, Wang Yunling, Gao Yingbin, Zhang Sitong, Ma Weirui, Liang Yaoji, Huang Deli
Abstract excerpt
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). To address this issue, we developed a novel therapeutic strategy based on multiparatopic antibodies that induce targeted degradation of EGFR, independent of driver mutations typically residing in the cytosolic domain. We engineered...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.